GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Merck & Co’s Japanese Subsidiary Inks Oncology and Metabolic Drug Discovery Deal with MerLion

  • MerLion Pharmaceuticals and Merck Banyu, the Japanese subsidiary of Merck & Co., signed a two-year drug discovery and licensing agreement.

    Under the new collaboration, MerLion and Banyu will identify new drug candidates from MerLion's natural product sample collection utilizing a range of validated targets in oncology and metabolic disease. MerLion will receive upfront payments and predefined milestones and royalties for the licensing of collaborative discoveries.

    MerLion has also extended its four-year agreement based on infectious disease targets with Merck & Co.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?